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Abstract
Cognitive impairment is increasingly recognised as an important potential adverse effect of 
medication. However, many drug development programmes do not incorporate sensitive cognitive 
measurements. Here, we review the rationale for cognitive safety assessment, and explain several 
basic methodological principles for measuring cognition during clinical drug development, 
including study design and statistical analysis, from Phase I through to postmarketing. The crucial 
issue of how cognition should be assessed is emphasized, especially the sensitivity of 
measurement. We also consider how best to interpret the magnitude of any identified effects, 
including comparison with benchmarks. We conclude by discussing strategies for the effective 
communication of cognitive risks.
Introduction
Assessing cognitive safety, in other words the impact of clinical treatments on the ability to 
perceive, process, understand, and store information, make decisions and produce 
appropriate responses, is an issue whose importance is increasingly recognised by the 
pharmaceutical industry, regulators, clinicians, and the public. In some cases (e.g., first-
generation antihistamines), marked cognitive-impairing effects were established many years 
ago, and warnings relating to possible sedation routinely appear on labelling [1]. More 
recently, there has been widespread concern about possible adverse effects of several 
commonly used drugs that, although not necessarily causing marked sedation, are likely to 
have important cognitive effects. For example, several epidemiological cohort studies report 
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that impaired cognitive function is associated with medications that have anticholinergic 
activity, particularly when taken in combination [2]. One large study in older patients 
reported consistently impaired scores on the Mini Mental State Examination (MMSE: a 
dementia rating scale) in those using medication with definite anticholinergic activity, after 
adjusting for several confounders [3]. Other studies reported that the use of anticholinergics 
is associated with increased risk of mild cognitive impairment (MCI) [4], and even with 
dementia in a dose-dependent fashion [5,6].
The above results present a clear cause for concern in older people, but it is also important to 
consider the potential impact of cognitive impairment on wellbeing and everyday function in 
younger populations. In the workplace, medication-induced cognitive impairment could 
result in reduced productivity, or ‘presenteeism’, and could be dangerous for those who drive 
or operate machinery as part of their jobs. At school or university, cognitive impairment 
could prevent students from fulfilling their academic potential, with implications for future 
competitiveness in the jobs market.
Medication-induced cognitive impairment also raises cause for concern outside work or 
study contexts: everyday tasks are likely to be adversely affected. Driving is one of the best 
studied of these, and initiatives such as the DRiving Under the Influence of Drugs, alcohol 
and medicines project (DRUID [7]) have highlighted classes of medicine that are likely to 
induce cognitive impairment, based on a review of the pharmacological, epidemiological, 
and experimental psychopharmacological literature. Laboratory studies examining alcohol 
administration (which is well known to impair driving performance and, therefore, can act as 
a standard reference [8]), have highlighted several core cognitive processes that, if disrupted 
by a drug, are likely to impair driving ability and warrant further investigation [9]. 
Additionally, there is an extensive literature on the effects of common medicines on actual 
driving ability, measured using either a specially instrumented vehicle on a public highway 
in normal traffic or a driving simulator [10], which has identified several drug classes that 
are likely to increase the risk of road traffic accidents [11].
Whereas driving ability has been particularly well studied, and warnings not to drive or 
operate machinery have appeared on medication labelling for decades, these are not the only 
important aspects of everyday function that are likely to be affected if cognition is disrupted. 
This issue is well recognised in the literature on cognitive decline in older individuals, which 
focuses on activities of daily living (ADL) [12]. Use of communication devices (and 
technology more generally), managing finances, cooking meals, shopping, navigation, and 
housework can all be adversely affected by medication-induced cognitive impairment. 
Everyday tasks that are more cognitively demanding (often termed ‘instrumental’ ADLs), 
such as passing on a message to another person, finding the way in an unfamiliar place, or 
taking part in a conversation, are particularly affected when cognitive ability is disrupted 
[13], and are frequently impaired early in the course of cognitive decline. Such impairment 
of everyday function substantially reduces quality of life in patients and is a major 
contributor to burden on caregivers [14]. The association between cognitive impairment and 
ADL is also pronounced in younger individuals with mental illness, for example 
schizophrenia [15] and bipolar disorder [16]. Indeed, several studies have found that in those 
recovering from schizophrenia, cognitive performance predicts resumption of normal 
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function (such as the ability to live independently, participate in leisure activities, and return 
to the workplace) better than symptoms [17].
Cognitive impairment clearly represents an important possible adverse effect of medication. 
Regulators are likely to demand, and consumers have the right to be informed about, 
possible cognitive risks. However, the degree to which many medications influence cognitive 
function remains unknown. In this article, we outline experimental approaches to 
determining whether a drug impacts cognition, discussing: (i) the rationale for assessing 
cognition during clinical development; (ii) drug classes likely to affect cognition; (iii) study 
design, populations and analysis; and (iv) the importance of using sensitive and 
comprehensive measurements. We conclude by considering how to interpret any effects 
detected, and strategies for communicating the potential implications of any findings to 
regulators and consumers.
Why is it important to assess cognition during clinical drug development?
Assessment of safety and tolerability (e.g., cardiovascular effects, changes in liver enzymes, 
neurological events, etc.) is a crucial component of early-phase clinical studies. A decision 
to progress a candidate compound to later phases depends on the outcome of these studies. 
Many central nervous system (CNS) and non-CNS compounds have the potential to affect 
cognitive ability detrimentally, and the risks have been highlighted for particular drug 
classes [18–21]. Drugs can have multiple pharmacological effects, some of which are 
desirable (related to mechanism and/or target of interest) and some undesirable (‘off-target’, 
or other pharmacology leading to adverse effects, such as cognitive dysfunction). If a drug 
impairs cognition, this might be related to off-target pharmacological effects known to 
impair cognition (e.g., blockade of muscarinic, histaminergic, or beta adrenergic receptors). 
Given the greater awareness of potential cognitive impairment by regulators [e.g., US Food 
and Drug Administration (FDA) advice on statin risks: http://www.fda.gov/Drugs/
DrugSafety/ucm293101.htm], as well as the general public, changes in cognition are 
increasingly assessed using objective measures during clinical development to examine the 
potential short- and long-term cognitive risks. As such, assessment of cognitive function can 
be an integral part of decision making during clinical development.
Information on the cognitive profile of a compound could be informative for several reasons 
and can aid decision making during clinical development. For example, adverse effects on 
cognitive function might be important for: (i) determining dose–response relationships and 
selecting safe doses for later phase development (including the need for titration); (ii) 
differentiation from competitor drugs in relation to cognitive safety; (iii) detecting off-target 
pharmacological effects (i.e., other pharmacology unrelated to the target of interest); and (iv) 
assessing the risk:benefit ratio in relation to the target indication. In addition, it might also 
be worthwhile to continue to assess cognitive safety following approval and marketing 
through monitoring of cognitive function as part of routine pharmacovigilance, which is 
increasingly feasible through the use of internet- or app-based assessments. Longer-term 
monitoring of cognition might be particularly useful in detecting effects of drug–drug 
interactions on cognitive function (Fig. 1), especially in individuals with multiple co-
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morbidities (for whom polypharmacy is the norm), because such patients are usually 
excluded from clinical trials.
Regulatory expectations and compliance
The importance of assessing cognition during clinical development is outlined in several 
FDA guidance documents. For example, in guidance document UCM126958, published by 
both the Center for Drug Evaluation and Research and the Center for Biologics Evaluation 
and Research, the FDA highlights the fact that certain types of adverse effect are likely to go 
undetected if specific, sensitive measurements are not used [22]. This document 
recommends that, when a drug has the potential for such effects, additional testing or 
specific assessments will be required. As an example, it states: ‘for a new drug with 
recognised CNS effects (especially sedating effects), sponsors should conduct an assessment 
of cognitive function, motor skills, and mood’.
More recent FDA guidance provides an even clearer expectation of cognitive safety 
assessment during clinical development. The draft document UCM430374 discusses the 
evaluation of drug effects on the ability to operate a motor vehicle (http://www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM430374.pdf). It states: ‘Beginning with first-in-human studies, all drugs, including 
drugs intended for non-CNS indications, should be evaluated for adverse effects on the 
CNS… The occurrence of adverse CNS events in even a small number of phase 1 subjects 
can indicate the need for more focused studies of CNS effects. Early testing for CNS effects 
should generally emphasize sensitivity over specificity … measures of reaction time, divided 
attention, selective attention, and memory may be appropriate’. These regulatory 
expectations warrant the use of specific, targeted, and sensitive cognitive safety assessments, 
because routine monitoring will at best underestimate adverse effects and at worst fail to 
detect them completely.
The extent to which better monitoring of cognitive outcomes during drug development can 
lead to better regulated medicines is increasingly recognised as important in the wider 
regulatory context. Although assessments establishing the cognitive effects of drugs have 
been applied in pharmacological studies since the late 1960s [23], the use of objective tests 
(as opposed to self-report measures) has typically not been a requirement of regulatory 
bodies. Additionally, those early studies that did use objective cognitive assessments during 
the drug development process often focused on psychomotor function or processing speed, 
and did not examine higher-order cognitive processes, such as executive function, social 
cognition, or specific components of memory. Consequently, objective cognitive assessment 
has not been conducted as consistently or comprehensively as other types of safety 
assessment during clinical development, resulting in uncertainty about the cognitive impact 
of many commonly used medicines [24]. Therefore, it is of clear regulatory interest to 
incorporate such exercises into ongoing safety monitoring for currently marketed drugs.
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Compounds likely to have a negative impact on cognition
CNS disorder drugs
Broadly speaking, any drug that is CNS penetrant (i.e., crosses the blood–brain barrier) can 
influence cognition through effects on neurotransmitter systems, such as dopamine, 
acetylcholine, noradrenaline, glutamate, GABA, histamine, adenosine, and serotonin. More 
specifically, compounds that boost the function of specific neurotransmitter systems (e.g., 
agonists, reuptake inhibitors, or releasers), or block transmission in these systems (e.g., 
antagonists at postsynaptic receptors) might influence cognition. This includes many 
compounds developed for neurological disorders, such as epilepsy (i.e., anticonvulsants) and 
chronic pain, as well as neuropsychiatric disorders (reviewed in [2,25–30]). The effects of 
compounds on cognitive function might be nonlinear; for example, following an inverted-U 
function, as observed for drugs affecting the dopamine system, with either too little or too 
much transmission impairing cognition [31]. Such effects are not simply of academic 
interest; they are highly relevant for drugs in development for Parkinson’s disease (i.e., 
modulators of dopamine transmission) because it is likely that, although motor symptoms 
might be improved, there could be detrimental effects on specific cognitive processes 
[32,33]. In the specific case of drugs that stimulate dopamine D2/D3 receptors, this might 
include unwanted influences on reward processing and/or impulsivity [34], which are 
warning flags for abuse liability.
Non-CNS disorder drugs
Whereas the potential for drugs developed for CNS disorders to impact cognitive function 
detrimentally is clear, there are also many classes of compound developed for non-CNS 
disorders that confer a risk of cognitive impairment. Known examples include those 
developed for cardiovascular disorders [18,21], obesity [19], oncology [35,36], genitourinary 
disorders (e.g., overactive bladder [37,38]), and allergies [39]. In many cases, it is unclear 
what processes are responsible for the deleterious effects on cognition. However, possible 
mechanisms include: (i) indirect effects on central neurotransmission; (ii) effects on 
metabolic function (e.g., glucose, hormones); (iii) effects on the immune system (e.g., 
cytokines), which communicates extensively with the CNS; and (iv) other adverse events 
(e.g., nausea or pain). There is also growing evidence that the integrity and permeability of 
the blood–brain barrier can be compromised by many common medical conditions, 
including systemic diseases (e.g., diabetes, hypertension, and hypercholesterolemia), 
inflammatory conditions (multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer’s 
disease and Parkinson’s disease), infections such HIV, stroke, traumatic brain injury, and 
brain tumours [40–42]. Furthermore, the function of the blood–brain barrier can be altered 
by certain medications, environmental toxins, and the ageing process itself [41]. Therefore, 
there exists the potential for many new and commonly used drugs to gain access to the brain 
and have an unanticipated impact on cognitive function, in both clinical trials and real-world 
settings.
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Study design and analysis
Epidemiological cohort studies can provide suggestive evidence that a drug might influence 
cognition, and often benefit from large sample sizes resulting in robust statistical inference. 
However, experimental clinical studies, in particular double-blind, randomised controlled 
trials (RCTs), should be considered the gold standard when assessing cognitive safety. 
Although epidemiological studies enjoy the benefits of population samples, they are purely 
observational and, therefore, can be subject to confounding, by measured or unmeasured 
variables, meaning that causal inferences can be difficult. Drawbacks of RCTs include that 
they are time consuming to conduct and costly, and that the sample tested might not be 
completely representative of the population that will eventually take the drug. However, 
ultimately, they provide the best quality of evidence addressing the question of cognitive 
safety and, therefore, represent high value for money.
Phase I
In Phase I trials, cognitive impairment can be considered either at the level of the individual 
subject or across groups, alongside other commonly assessed adverse events. Inferential 
statistics might or might not be conducted, but examining patterns in cognitive data will 
nonetheless be informative. Cognitive assessments typically produce continuous 
measurements, and large databases of normative scores exist for many commercially 
available tests; meaning that the normal range in performance (given a subject’s age and 
educational level) can be calculated and used to determine the likely importance of any 
observed fluctuations. The standard approach to cognitive assessment in clinical trials is to 
take measurements both after drug administration and at baseline (usually the point of 
randomisation); including the latter in statistical analyses improves sensitivity because 
natural interindividual variability in performance can be accounted for.
One possible approach to declaring a cognitive adverse event would be if a subject scored 
within the normal range at baseline, but following drug administration performance dropped 
below a threshold based on the reliable change (RC) index, a metric derived from the test–
retest reliability of a measure [43]. For cognitive measures, the RC index might need to be 
adjusted for practice effects (because people’s scores naturally improve following repeated 
exposure to the same test). Such a categorical approach might be particularly useful in small 
Phase I studies, but inferential statistics would not usually be performed. Isolated incidents 
of poor cognitive performance would not necessarily preclude further drug development, 
although they might flag up areas for consideration in later phases.
Alternatively or additionally, cognitive scores before and after drug administration can be 
averaged within dose groups and compared statistically with an active or nonactive 
comparator. However, often such comparisons will be limited by poor statistical sensitivity 
(see below), even after accounting for baseline performance, because of the low numbers of 
subjects typically included in Phase I studies. As such, results from Phase I cognitive 
assessments would usually not be considered conclusive. Depending on the target indication, 
if consistent cognitive safety signals were observed across most or all subjects, this might 
form part of the basis of a decision not to progress a compound through the development 
pipeline, because of the possibility that the degree of impairment induced might outweigh 
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the potential clinical benefit. Therefore, checking cognitive effects early in development 
could contribute meaningful information to risk management and go/no-go decisions.
Phases II and III
Cognitive safety is also considered at the group level beyond Phase I, averaging observations 
over dozens or hundreds of individuals per study arm. However, assessing cognitive safety 
raises some important design and statistical challenges.
Superiority designs—By its nature, demonstrating cognitive safety requires asking a 
very different question to that addressed in standard ‘superiority’ trials, where the aim is to 
determine whether a drug performs better than some comparator (e.g., placebo, a lower dose 
of the same compound, or an existing in-market drug). A desirable outcome in superiority 
trials is to show a difference between the conditions. The standard (Neyman–Pearson, or 
frequentist) statistical framework derives a P value: the probability that a pattern of results at 
least as extreme as that observed would occur under the null hypothesis (H0: that the drug 
under study and the comparator have the same effect). If the P value falls below a 
prespecified value (alpha, the tolerance for the frequency of false positives; conventionally 
set at 5%), the result is declared significant and H0 is taken to be rejected. In the frequentist 
framework, the interpretation of a significant P value in the context of a superiority trial as 
supporting a rejection of the null is logically unambiguous (at a given false positive 
tolerance level).
By contrast, demonstrating ‘cognitive safety’ requires asking a different question: in this 
case, a desirable result will often be to conclude that there is no difference between a drug 
and some comparator. Adopting a strict interpretation of cognitive safety, we might wish to 
ask whether cognitive function while taking a drug is no worse than if the drug had not been 
administered. Using a standard placebo-controlled RCT, failing to show a significant 
difference between an active treatment and a nonactive comparator is not, by itself, sufficient 
to demonstrate cognitive safety. This is because failing to show a significant difference can 
be an ambiguous result in the frequentist statistical framework: absence of evidence is not 
necessarily evidence of absence. A nonsignificant P value can leave the investigator trapped 
in the logical straightjacket of a triple negative: a failure (1), to reject (2), the null (3); a 
position from which it can be difficult to draw any meaningful conclusions at all. Therefore, 
P values cannot, by themselves, provide evidence in favour of H0, and the notion of a result 
being ‘highly nonsignificant’ is logically meaningless [44].
A nonsignificant result could reflect a true negative; in other words, there is genuinely no 
difference in the cognitive impact of the drug and the comparator. However, nonsignificance 
could also occur even when a difference truly exists, because of low sensitivity (i.e., a false 
negative). A common reason for false negatives is low statistical power; that is, not including 
enough subjects to detect an effect of a magnitude considered clinically important. This must 
be addressed before the study with a power calculation. If a minimally important effect size 
can be specified in advance (which can itself pose a challenge), then the number of subjects 
required to reject the null hypothesis (at given tolerance levels for false negatives and 
positives) can be calculated. To provide a credible demonstration that two conditions do not 
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differ, the tolerance for false negatives (Type II errors) needs to be controlled at a sufficiently 
low rate, just as the tolerance level for false positives (Type I errors) needs to be controlled 
in superiority designs, perhaps also at 5%. This requires large samples. For example, with 
the false positive and false negative rates both set to 5%, testing for an effect of standardised 
mean difference (SMD, Cohen’s d) = 0.3 (equivalent to a typical antidepressant effect size 
[45]) would require nearly 250 individuals in each arm using a one-tailed statistic (300 if a 
two-tailed test were planned, additionally allowing for the possibility that the drug under 
study improves cognition). Assuming that the sensitivity of measurement can be assured (see 
section on ‘Measurement of cognition’ below) a nonsignificant result arising from an 
adequately powered superiority RCT could be interpreted as indicating that the effect of the 
drug in question on cognition is no greater, relative to the comparator, than the effect size 
specified in the power calculation.
Noninferiority designs—Another option, adopting a slightly different interpretation of 
cognitive safety, would be to use a ‘noninferiority’ design [46], in which the drug under 
study is compared against an active comparator. Noninferiority trials are often used to 
establish efficacy in situations when administering placebo would be considered unethical, 
for example when an established treatment is clearly effective and to administer placebo 
would expose patients to serious risk. Such designs allow the conclusion that a new drug is 
‘no less effective’ (within some margin; see below) than an existing compound with 
established efficacy. The logic in the context of a study on cognitive safety is slightly 
different. If a comparator drug has a clearly detrimental influence on cognition, with a well-
established effect size (which might be considered acceptably low), it can act as a 
benchmark for the drug under study. If noninferiority can be demonstrated, it can be 
concluded that the drug under study is at least ‘no more detrimental’ (within some margin) 
than the active comparator.
In such designs, it is necessary to define a noninferiority margin (M): the extent to which the 
drug under study could perform worse than the active control but still be considered 
similarly effective (or harmful, in the case of safety). The starting point for specifying M is 
the expected effect of the active comparator relative to placebo, usually known before the 
study commences from existing data. FDA guidance states that M can be ‘no larger than the 
entire effect that [the active control] is presumed to have had [relative to a placebo condition, 
had it been included]’ (http://www.fda.gov/downloads/Drugs/Guidances/UCM202140.pdf). 
Typically, a smaller (i.e., more conservative) estimate of M than this will be used. For 
example, it might be decided that M should lie within some percentage of the effect of the 
active control; alternatively or additionally, confidence intervals from historical data and/or 
clinical judgment might be used. To demonstrate noninferiority, the 95% confidence interval 
derived from the contrast of the drug under study against the active comparator should not 
overlap with M.
Although specification of M poses a challenge in conducting and interpreting such studies, it 
is arguably no greater than the challenge in specifying a minimally interesting effect size 
when calculating statistical power in a superiority design. However, if a conservative (i.e., 
small) M is adopted, large sample sizes might be required. As well as the potential to 
demonstrate noninferiority, a further possibility is that cognitive performance is actually 
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significantly better following administration of the drug under study than the active 
comparator (similar to a superiority design). Therefore, it is useful to allow for the additional 
possibility of subsequent testing for superiority over the active comparator (assuming that 
noninferiority has already been demonstrated), because this would permit an unambiguous 
demonstration of (relative) cognitive safety if statistical significance were achieved.
Hybrid designs—The usual aim in noninferiority studies is to demonstrate that the drug 
under study performs no worse that the active comparator, within the margin, M. This can be 
achieved using a two-arm design (http://www.fda.gov/downloads/Drugs/Guidances/
UCM202140.pdf). Such a design assumes that the M can be specified confidently and 
appropriately on the basis of historical data (the ‘constancy’ assumption); however, this is 
not always the case. For example, data might not be available examining the contrast of the 
active comparator against placebo on a particular cognitive measure, or in a specific 
population. To facilitate the specification of M in such cases, it might be useful to 
incorporate an additional nonactive (i.e., placebo) comparator condition, allowing for an 
empirical estimation.
A convincing result supporting cognitive safety from such a design would be to demonstrate 
two effects: (i) the active comparator impairs cognition significantly relative to placebo. This 
demonstrates study (and measurement) sensitivity. The placebo data can then also be used to 
inform the estimate of M; and (ii) after M has been specified, the drug under study can then 
be tested for noninferiority relative to the active comparator. If both (i) and (ii) yield 
significant results, this design enables the conclusion of noninferiority using an empirically 
informed M. However, if (i) fails to achieve significance, this indicates poor study 
sensitivity, possibly because the sample size was not sufficiently large, or the measurement 
was not sufficiently sensitive.
Further design and analysis considerations
Bayesian analysis—An alternative statistical approach would be to use a Bayesian 
procedure, which takes a complementary perspective to the standard frequentist framework 
to make inference. Instead of computing the probability of the observed data, conditioned on 
H0, the Bayesian approach computes the probability of the hypothesis in question, 
conditioned on the observed data. Note that the term ‘probability’ in the Bayesian 
framework is applied to hypotheses, not data, so strictly refers to subjective, not objective 
probability; that is, confidence: how certain one is that a particular hypothesis is correct. 
Bayesian inference also requires the specification of ‘priors’; that is, pre-study predictions 
about experimental data (although if these are specified weakly, they have little influence on 
the conclusions drawn). The observed data are combined with the priors through application 
of Bayes’ rule to create a ‘posterior’ estimate, together with a ‘credibility interval’ (the 
Bayesian equivalent of a confidence interval), which provides the basis for inference.
The particular value of Bayesian statistics in the assessment of cognitive safety is that it 
allows firm conclusions to be drawn supporting the null hypothesis. Bayesian statistics can 
also incorporate existing data in priors (e.g., the performance of individuals administered 
placebo, perhaps established through previous work), which might allow for a smaller 
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number of subjects to be tested. Finally, Bayesian inference can allow strong conclusions to 
be drawn on the basis of relatively small datasets (see [47] for a discussion).
Missing data—Missing data are important to consider in any trial, but particularly in the 
context of cognitive safety, regardless of the design or analysis used. If a drug is cognitively 
impairing, then this effect itself could conceivably increase the chance that participants will 
drop out of the trial, or fail to attend or complete a testing session. If this occurs, and the 
probability that a data point is missing depends on this unobserved value, then the data are 
‘missing not at random’ (MNAR), which could bias subsequent analysis towards a null 
effect if a per-protocol analysis is used. In other words, a per-protocol analysis could fail to 
detect a genuine cognitive safety signal (false negative) because the subjects who were most 
cognitively impaired by the drug were not tested. However, intent-to-treat analysis with last-
observation-carried-forward (LOCF) is also not an advisable strategy in cognitive safety 
trials. It will be biased towards showing no difference when data are MNAR, because LOCF 
will tend to underestimate effects. This strategy results in a more conservative analysis in the 
context of testing for efficacy, but a more liberal one in the context of cognitive safety. Thus, 
correcting for MNAR data in the context of cognitive safety is not trivial and careful 
consideration needs to be given to the method used to account for it.
Study population and time period
Important questions for any trial are what study populations should be considered and over 
what time period. It is likely that initial cognitive safety studies will be conducted in healthy 
volunteers, which should explore a range of doses over a variety of timescales. Single dose 
(acute) or repeated dose (chronic) both need to be considered, depending on whether the 
drug in question is intended for use over an extended period of time.
However, even if studies in healthy volunteers provide results consistent with cognitive 
safety, it would still be important to test the cognitive effects of a drug in patient populations. 
Indeed, it is possible that cognition might be adversely affected by a given drug in healthy 
volunteers, while in the target patient population effects on cognition are minor (because the 
concomitant alleviation of symptoms can have a positive effect on cognitive function). For 
example, donepezil is known to impair cognition in healthy volunteers [48], but nonetheless 
is approved as a treatment for dementia. It is also possible that the cognitive effects of a drug 
might interact with developmental stage in younger populations (with potentially important 
implications for academic attainment if patients are still studying), or neurodegeneration in 
older or cognitively vulnerable individuals. Finally, cognitive effects of drugs might occur 
cumulatively, as shown by the example of anticholinergic load outlined in the introduction; 
therefore, additive or interactive effects with other drugs might be important to consider 
(Fig. 1). This has important implications for real-world clinical practice, because clinicians 
assessing risk and prescribing need to consider other drugs that their patients might be 
taking.
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Measurement of cognition
Broadly speaking, cognitive assessments measure an individual’s information processing 
capacity, including concentration, storage, and control (Fig. 2). The sensitivity and 
comprehensiveness of measurement is a crucial consideration in cognitive safety studies, 
especially in the common situation that inference will be based on statistically nonsignificant 
results. Even in an otherwise adequately powered study, a misleading nonsignificant result 
could arise if an insensitive instrument was used to assess cognition, or was applied 
incorrectly. Therefore, it is important to utilise sensitive, standardised cognitive assessments 
that have demonstrated sensitivity to cognitive impairment. The measurements used should 
also have adequate test–retest reliability and low practice effects to maximise sensitivity. A 
common strategy has been to assess cognitive impairment through self-report questionnaires 
[19]. However, in many cases, individuals will not have good insight into their own cognitive 
ability, so this might be insufficient to exclude all but the most pronounced effects on 
cognition.
Choosing appropriate tests for the study population in question is another important aspect 
of cognitive safety. If a test is too easy or too difficult then sensitivity will be compromised 
because of measurement boundary effects. For example, a test such as the MMSE (routinely 
used in the detection of dementia) will not be suitable to detect effects in young healthy 
subjects. Ideally, the test used should incorporate different levels of difficulty, which might 
be adjusted adaptively, furnishing sensitivity to detect cognitive impairment across the range 
of ability.
Until the late 1960s, cognitive assessments almost exclusively used traditional paper-and-
pencil measures, many of which were based on tests originally developed for the US Army 
to screen recruits. These tests are still used as part of standardised neuropsychological 
assessment in clinical settings. However, from the 1970s onwards, investigators began to use 
computerised testing to assess the cognitive effects of drugs [23], including automated 
versions of earlier paper-and-pencil tests [49] as well as new tests intended to assess specific 
domains of cognitive function [24]. The advent of automated computerised testing saw 
several improvements in the measurement of cognition. These include: increased precision 
of measurement, especially in relation to response speed; standardised timing of presentation 
of stimuli; greatly reduced potential for administrator errors or bias; improved portability; 
and increased efficiency (because data do not require digitisation before analysis). 
Automated computerised tests also have the advantage that they can be administered by less 
specialist staff, at substantially lower cost. However, despite these advantages, such 
cognitive assessments have not been used routinely as safety assessments during clinical 
development.
The term ‘cognition’ covers a range of processes, including (among others) perception, 
working memory (maintaining information ‘on-line’), episodic memory, sustained attention, 
decision making, and motor performance. Therefore, it is desirable to incorporate multiple 
tests into any assessment (although investigators might decide to focus on cognitive 
functions likely to be affected by the particular mechanism of action of the drug). For 
example, if memory is not assessed at all during cognitive assessment, then the study cannot 
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draw any conclusions about the effects of the drug on this process, which might obscure 
potential implications for everyday function. Importantly, it is possible that a drug could 
impair certain cognitive processes while leaving others intact, resulting in a profile of 
cognitive impairment. The use of a range of cognitive measures is also an important 
statistical consideration, because it will increase the number of comparisons made and 
thereby the false positive rate. One possible solution is to compute a composite measure 
across tests, but this approach is only valid when the tests all assess a common process.
Interpreting a cognitive safety signal
A challenge associated with the assessment of cognition is the interpretation of any signals 
observed. In addition to the statistical methods discussed above, it is important to 
communicate the magnitude of any detrimental effects in context. While statistically 
significant impairments might be detected, it does not automatically follow that these will be 
clinically meaningful.
Several possible approaches can be used to decide whether an effect is clinically meaningful. 
One would be to determine whether the estimated effect size of the impairment falls within 
conventional limits for small, medium or large effects. Following Cohen’s convention [50], 
an effect size (SMD) of <0.3 might be considered small, and might not be clinically 
meaningful. However, unlike efficacy studies, in which one might feel comfortable in 
accepting effect sizes of SMD < 0.3 as not clinically meaningful, a more risk-averse 
perspective might be warranted when considering cognitive safety. Hence, the criterion for 
nonclinical relevance might need to be more stringent; for example, an effect size of SMD < 
0.2 or lower. However, the precise level set would also need to consider the risk–benefit 
profile for the drug under study in relation to the target indication. When incorporating 
multiple tests to assess cognition across cognitive domains, the domain or combination of 
domains affected might further contribute to the evaluation of whether an effect is a 
clinically meaningful. The criterion should be set proportionately more strictly for 
indications where the risks of treatment might outweigh the benefits (e.g., developmental 
conditions).
One could also consider the effect size detected relative to that observed in neuropsychiatric 
disorders; for example, impairments of SMD = 1.5 (or higher) occur in cognitive disorders, 
such as dementia or MCI [51]. Schizophrenia and depression, in which cognitive 
impairments are considered core symptoms, are associated with impairments of around 
SMD = 1 and SMD = 0.5, respectively [52,53]. Typically, SMDs of 0.65 or greater 
(equivalent to around a ten-point drop in performance IQ) would be considered clinically 
relevant; hence, an impairment of this magnitude would indicate a clinically significant 
safety signal.
An alternative approach is to benchmark any observed cognitive safety signals against 
socially acceptable levels of impairment. In this regard, considering the impairment elicited 
by alcohol at the legal driving limit (i.e., 0.05–0.07 g/dL in most countries), overnight sleep 
deprivation, or healthy ageing might be useful. For example, this approach was used in 
assessing the safety risk of a novel compound, GSK1521498, in Phase I development for 
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obesity/addiction [54] (Fig. 3). In this study, a 5-mg dose of the sedative drug zolpidem 
(active comparator), which causes a decrement in reaction time during sustained 
concentration similar to the minimum impairment elicited by alcohol at 0.05 g/dL 
(approximately 25 ms, SMD approximately 0.7) [55], was used to examine the cognitive risk 
associated with GSK1521498 in a comparative manner. As expected, 5-mg zolpidem caused 
a significant reaction time impairment (approximately 25 ms), confirming the sensitivity of 
the cognitive measurement and study design. However, most effects of GSK1521498 on 
cognition were nonsignificant relative to placebo, and those impairments observed were 
numerically smaller than that caused by zolpidem (approximately 20 ms averaged across 
three time points at the highest dose), indicating a relatively low cognitive safety risk and 
supporting the continued clinical development of the compound.
Concluding remarks
Here, we have reviewed the rationale for examining cognitive safety during clinical 
development, possible study designs and analytic approaches, considerations relating to 
measurement sensitivity, and strategies for interpreting and communicating any cognitive 
safety signals. This field is still at an early stage, and precisely what designs should be 
adopted, what outcome measures should be used, and what statistical approaches are most 
appropriate will vary depending on the drug in question and the indication. Although we 
have proposed some approaches that might be useful and made some initial 
recommendations, there is as yet no consensus on the best way to demonstrate cognitive 
safety, or even how this term should be interpreted. Ultimately, prescribing medication is 
about weighing up the potential for risks and benefits. Even if a drug is shown to induce 
some cognitive impairment, it might still be beneficial to prescribe it; but pharmaceutical 
companies, regulators, clinicians, and patients need to understand the possible cognitive 
risks, and their implications for everyday function.
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FIGURE 1. 
The effect of an antipsychotic and a benzodiazepine drug on reaction times when 
administered in combination is greater than the sum of each separately, indicating a drug–
drug interaction. At the time of maximum impairment (3 h), responses on a choice reaction 
time test were slowed by approximately 30 ms by the antipsychotic, approximately 50 ms by 
the benzodiazepine [greater than the effect of blood alcohol concentration (BAC) of 0.05 
g/dL, the legal driving limit in many countries], but by approximately 175 ms when these 
were administered in combination (greater than the effect of BAC of 0.1 g/dL). If driving at 
a speed of 100 kph (60 mph), a slowing of response of approximately 175 ms is equivalent 
to an increased stopping distance of approximately 4.9 m (approximately 15 ft), the length 
of a large sedan car.
Source: Unpublished data, kindly provided by Otsuka Pharmaceutical Co., Ltd.
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FIGURE 2. 
Commonly assessed components of cognition, broadly split into the domains of input, 
storage, and control.
Source: Reproduced, with permission, from Cambridge Cognition.
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FIGURE 3. 
Results from a Phase I study of the comparative effect of 5-mg zolpidem (benzodiazepine 
with sedative properties: left side of figure) and GSK1521498 (µ-opioid inverse agonist in 
development for obesity and/or addiction: middle–right side of figure) on reaction times 
during a test of attention. Zolpidem (Zolp) slowed responses, relative to placebo, to 
approximately the same degree as previously shown at a blood alcohol concentration of 0.05 
g/dL (approximately 25 ms, green points [55]). Even at the highest dose tested, the average 
impairment caused by GSK1521498 (approximately 20 ms, red/orange points) was lower 
than that caused by 5-mg zolpidem, consistent with a relatively low cognitive risk and 
supporting the continued clinical development of the compound. Abbreviation: PBO, 
placebo.
Source: Reproduced, with permission, from [54].
Roiser et al. Page 19
Drug Discov Today. Author manuscript; available in PMC 2016 May 12.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
